EREG and colorectal carcinoma: As such, there have been several attempts since to validate EREG and AREG as biomarkers by retrospectively analyzing pretreatment specimens from metastatic or advanced CRC patients administered cetuximab or panitumumab with or without chemotherapy, as summarized in Table 1.